Skip to main content
SpringerLink
Log in

Vareniclin – Erhöhtes kardiovaskuläres Risiko bei der Raucherentwöhnung?

Varenicline – Increased cardiovascular risk in smoking cessation?

  • Klinische Pharmakologie
  • Published:
Der Kardiologe Aims and scope

Zusammenfassung

Rauchen stellt einen der wichtigsten kardiovaskulären Risikofaktoren dar. Vareniclin, ein Partialagonist am nikotinischen α4β2-Acetylcholinrezeptor, ist aktuell das wirksamste Medikament zur Raucherentwöhnung. Eine Behandlung mit Vareniclin wurde jedoch auch mit z. T. schweren kardiovaskulären Nebenwirkungen in Verbindung gebracht. Dieser Artikel beurteilt die aktuelle Datenlage zum kardiovaskulären Risiko einer Vareniclintherapie.

Abstract

Smoking is one of the most important cardiovascular risk factors. Varenicline, a partial agonist of the α4β2 nicotinic acetylcholine receptor, has been demonstrated to be the most efficacious medication for smoking cessation. However, treatment with varenicline has sometimes been associated with severe cardiovascular side effects. This article discusses the current data with respect to the cardiovascular safety of varenicline therapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. Alper BS (2011) Varenicline: quantifying the risk. CMAJ 183(12):1405

    PubMed  Google Scholar 

  2. Centers for Disease Control and Prevention (US), National Center for Chronic Disease Prevention and Health Promotion (US), Office on Smoking and Health (US) (2010) How tobacco smoke causes disease: the biology and behavioral basis for smoking-attributable disease, a report of the surgeon general. Centers for Disease Control and Prevention (US), Atlanta

  3. Champix® Fachinformation. Pfizer Limited. Stand Januar 2012

  4. Chi YW, Jaff MR (2008) Optimal risk factor modification and medical management of the patient with peripheral arterial disease. Catheter Cardiovasc Interv 71(4):475–489

    Article  PubMed  Google Scholar 

  5. Chow CK, Jolly S, Rao-Melacini P et al (2010) Association of diet, exercise, and smoking modification with risk of early cardiovascular events after acute coronary syndromes. Circulation 121(6):750–758

    Article  PubMed  Google Scholar 

  6. Coe JW, Brooks PR, Vetelino MG et al (2005) Varenicline: an alpha4beta2 nicotinic receptor partial agonist for smoking cessation. J Med Chem 48:3474–3477

    Article  PubMed  CAS  Google Scholar 

  7. Critchley JA, Capewell S (2003) Mortality risk reduction associated with smoking cessation in patients with coronary heart disease: a systematic review. JAMA 290(1):86–97

    Article  PubMed  Google Scholar 

  8. Critchley JA, Capewell S (2012) Smoking cessation for the secondary prevention of coronary heart disease. Cochrane Database Syst Rev 2:CD003041

    PubMed  Google Scholar 

  9. Dani JA, Bertrand D (2007) Nicotinic acetylcholine receptors and nicotinic cholinergic mechanisms of the central nervous system. Annu Rev Pharmacol Toxicol 47:699–729

    Article  PubMed  CAS  Google Scholar 

  10. Domburg RT van, Meeter K, Berkel DF van et al (2000) Smoking cessation reduces mortality after coronary artery bypass surgery: a 20-year follow-up study. J Am Coll Cardiol 36(3):878–883

    Article  PubMed  Google Scholar 

  11. European Medicines Agency confirms positive benefit-risk balance for Champix (2012) 21 July 2011 EMA/579351/2011 Press Office. http://www.ema.europa.eu/docs/en_GB/document_library/Press_release/2011/07/WC500109177.pdf. Zugegriffen: March 15, 2012

  12. FDA Drug Safety Newsletter 2009, Postmarket Review Volume 2, Number 1,20092:1. http://www.fda.gov/Drugs/DrugSafety/DrugSafetyNewsletter/ucm110235.htm. Zugegriffen: March 15, 2012

  13. Gonzales D, Rennard SI, Nides M et al (2006) Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial. JAMA 296:47–55

    Article  PubMed  CAS  Google Scholar 

  14. Institute for Safe Medication Practices (2012) Strong safety signal seen for new varenicline risks. http://www.ismp.org/docs/vareniclinestudy.asp. Zugegriffen: March 15, 2012

  15. Jorenby DE, Hays JT, Rigotti NA et al (2006) Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial. JAMA 296:56–63

    Article  PubMed  CAS  Google Scholar 

  16. Mähönen MS, McElduff P, Dobson AJ et al (2004) Current smoking and the risk of non-fatal myocardial infarction in the WHO MONICA project populations. Tob Control 13(3):244–250

    Article  PubMed  Google Scholar 

  17. Rigotti NA, Pipe AL, Benowitz NL et al (2010) Efficacy and safety of varenicline for smoking cessation in patients with cardiovascular disease: a randomized trial. Circulation 121:221–229

    Article  PubMed  CAS  Google Scholar 

  18. Roger VL et al (2011) Heart disease and stroke statistics-2011 update: a report from the American Heart Association. Circulation 123(4):e18–e209

    Article  PubMed  Google Scholar 

  19. Romero JR, Morris J, Pikula A (2008) Stroke prevention: modifying risk factors. Ther Adv Cardiovasc Dis 2(4):287–303

    Article  PubMed  Google Scholar 

  20. Sargent JD, Demidenko E, Malenka DJ et al (2012) Smoking restrictions and hospitalization for acute coronary events in Germany. Clin Res Cardiol 101(3):227–235

    Article  PubMed  Google Scholar 

  21. Singh S, Loke YK, Spangler JG, Furberg CD (2011) Risk of serious adverse cardiovascular events associated with varenicline: a systematic review and meta-analysis. CMAJ 183:1359–1366

    Article  PubMed  Google Scholar 

  22. Statistisches Bundesamt (2012) Gesundheitsrelevantes Verhalten (Mikrozensus 2009). http://www.destatis.de/DE/ZahlenFakten/GesellschaftStaat/Gesundheit/GesundheitszustandRelevantesVerhalten/Tabellen/Rauchverhalten.html?nn=50798. Zugegriffen: March 15, 2012

  23. Statistisches Bundesamt (2012) Todesursachen 2010. http://www.destatis.de/DE/ZahlenFakten/GesellschaftStaat/Gesundheit/Todesursachen/Aktuell.html?nn=50808. Zugegriffen: March 15, 2012

  24. Stead LF, Perera R, Bullen C et al (2008) Nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev (1):CD000146

    Google Scholar 

  25. Takagi H, Umemoto T (2011) Varenicline: quantifying the risk. CMAJ 183(12):1404

    PubMed  Google Scholar 

  26. Teo KK et al (2006) Tobacco use and risk of myocardial infarction in 52 countries in the INTERHEART study: a case-control study. Lancet 368(9536):647–658

    Article  PubMed  Google Scholar 

  27. Tonstad S, Tønnesen P, Hajek P et al (2006) Effect of maintenance therapy with varenicline on smoking cessation: a randomized controlled trial. JAMA 296:64–71

    Article  PubMed  CAS  Google Scholar 

  28. Weil J, Stritzke J, Schunkert H (2012) Risikofaktor „Rauchen“: Wege aus der Nikotinsucht bei Patienten mit kardiovaskulären Erkrankungen. Internist 53:45–50

    Article  PubMed  CAS  Google Scholar 

Download references

Interessenkonflikt

Der korrespondierende Autor gibt für sich und seinen Koautor an, dass kein Interessenkonflikt besteht.

Author information

Authors and Affiliations

  1. Abteilung Pharmakologie, Universitätsmedizin Göttingen, Robert-Koch-Str. 40, 37075, Göttingen, Deutschland

    M. Dewenter &  A. El-Armouche

Authors
  1. M. Dewenter
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. A. El-Armouche
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to A. El-Armouche.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Dewenter, M., El-Armouche, A. Vareniclin – Erhöhtes kardiovaskuläres Risiko bei der Raucherentwöhnung?. Kardiologe 6, 240–243 (2012). https://doi.org/10.1007/s12181-012-0425-8

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12181-012-0425-8

Schlüsselwörter

Keywords

Search

Navigation